Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > sciatica treatment market
Get a free sample of Sciatica Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Sciatica Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Sciatica Treatment Market size was valued at around USD 4.8 billion in 2023 and is expected to reach around USD 10 billion by 2032 at a CAGR of 8.3% during the forecast period. The increasing prevalence of sciatica coupled with growing awareness related to available treatments is anticipated to be among the primary factors propelling market growth.
The increasing burden of sciatica is driving the demand for early treatment due to its common occurrence and association with chronic pain, thereby leading to market growth over the analysis period. Factors like smoking, exposure to vibration at work, and excess body weight have been shown to influence the risk of hospitalization for sciatica. The increase in prevalence of conditions such as herniated disc, bone spurs, or rarely the tumor contributes to the increasing prevalence of the sciatica condition.
For instance, according to Mayo Clinic data published in January 2021, it was estimated that in the U.S., 80% of the population will experience low back pain at some point in their lives. This statistic underscores the high prevalence of low back pain, which can be caused by various factors including herniated discs. Hence, the increasing prevalence of such conditions is anticipated to be the prime cause of the growing need for the treatment of sciatica globally.
Sciatica treatment are medical interventions and therapeutic approaches aimed at alleviating the symptoms associated with sciatic nerve compression or irritation. Sciatica treatment typically involves a combination of approaches to relieve pain, reduce inflammation, improve mobility, and address the underlying cause of the condition.
The nonsteroidal anti-inflammatory drugs (NSAIDs) segment was valued at USD 2 billion in 2023 and will continue to gain traction through 2032, as they are more cost-effective, and are known for their effectiveness in reducing pain and inflammation.
The global sciatica treatment industry was valued at around USD 4.8 billion in 2023 and is expected to reach around USD 10 billion by 2032, driven by the increasing prevalence of sciatica, coupled with growing awareness related to available treatments.
North America sciatica treatment market accounted for USD 2 billion in 2023, favored by healthcare education initiatives targeting both healthcare professionals and the public.
Abbott Laboratories, Amneal Pharmaceuticals LLC., Bayer AG, Bristol Myers Squibb, Eliem Therapeutics, Novartis AG, Pfizer Inc., Scilex Holding, Sinfonia Biotherapeutics, and Sorrento Therapeutics.